Who are Kafocin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CEFPIRAMIDE, CEFOTIAM, CEFMENOXIME, Bl-S786R, Cefobid, Kefadol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cefaloglycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Kafocin — Competitive Intelligence Brief

Kafocin (cefaloglycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cefaloglycin. Area: Metabolic.

marketed cefaloglycin Bacterial penicillin-binding protein Metabolic Live · refreshed every 30 min

Target snapshot

Kafocin (cefaloglycin) — Eli Lilly.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kafocin TARGET	cefaloglycin	Eli Lilly	marketed	cefaloglycin	Bacterial penicillin-binding protein	1970-01-01
CEFPIRAMIDE	CEFPIRAMIDE		marketed	cefpiramide	Bacterial penicillin-binding protein	1989-01-01
CEFOTIAM	CEFOTIAM		marketed	cefotiam	Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein	1988-01-01
CEFMENOXIME	CEFMENOXIME		marketed	cefmenoxime	Bacterial penicillin-binding protein	1987-01-01
Bl-S786R	CEFORANIDE		marketed	ceforanide	Bacterial penicillin-binding protein, Penicillin-binding protein 1A	1984-01-01
Cefobid	CEFOPERAZONE		marketed	Cephalosporin Antibacterial	Bacterial penicillin-binding protein, Penicillin-binding protein 1A	1982-01-01
Kefadol	CEFAMANDOLE NAFATE	Eli Lilly	marketed	cefamandole nafate	Bacterial penicillin-binding protein	1978-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cefaloglycin class)

Eli Lilly · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kafocin — Competitive Intelligence Brief. https://druglandscape.com/ci/cefaloglycin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab